Last reviewed 2026-04-23 · How we verify

SR34006

SR34006 is a selective antagonist of the chemokine receptor CCR2, which blocks the recruitment of monocytes and inflammatory cells to sites of inflammation.

SR34006 is a selective antagonist of the chemokine receptor CCR2, which blocks the recruitment of monocytes and inflammatory cells to sites of inflammation. Used for Diabetic kidney disease.

At a glance

Mechanism of action

CCR2 is a G-protein coupled receptor expressed on monocytes and other immune cells that mediates their migration in response to chemokine ligands. By antagonizing CCR2, SR34006 reduces monocyte infiltration into inflamed tissues, thereby decreasing inflammatory responses. This mechanism has been explored for conditions characterized by excessive monocyte-driven inflammation.

Approved indications

• Diabetic kidney disease

Common side effects

No common side effects on file.

Key clinical trials

• Bioequipotency Study of Idrabiotaparinux and Idraparinux in Patients With Deep Venous Thrombosis of the Lower Limbs (PHASE3)
• Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach (PHASE3)
• Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation (PHASE3)
• SR34006 Compared to Placebo in Patients Who Have Completed 6 Months of Treatment for Symptomatic Pulmonary Embolism or Deep Vein Thrombosis (PHASE3)
• Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT) (PHASE3)
• Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation (AMADEUS) (PHASE3)
• SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.